As the pan-European STOXX Europe 600 Index experiences modest gains amid easing geopolitical tensions and robust corporate earnings, the small-cap segment in Europe presents intriguing opportunities for investors. In this environment, identifying stocks with solid fundamentals and insider activity can provide valuable insights into potential growth prospects within the small-cap space.
Top 10 Undervalued Small Caps With Insider Buying In Europe
Name
PE
PS
Discount to Fair Value
Value Rating
|
CellaVision
|
21.4x
|
3.9x
|
43.24%
|
★★★★★★
|
|
Eurocell
|
10.6x
|
0.3x
|
45.49%
|
★★★★★☆
|
|
everplay group
|
7.6x
|
2.4x
|
3.84%
|
★★★★★☆
|
|
THG
|
NA
|
0.3x
|
33.12%
|
★★★★★☆
|
|
Bilia
|
15.5x
|
0.3x
|
44.66%
|
★★★★☆☆
|
|
Morgan Advanced Materials
|
NA
|
0.6x
|
35.54%
|
★★★★☆☆
|
|
ABL Group
|
NA
|
0.4x
|
0.82%
|
★★★★☆☆
|
|
Cloetta
|
20.6x
|
1.8x
|
27.77%
|
★★★☆☆☆
|
|
Young’s Brewery
|
39.6x
|
0.9x
|
21.64%
|
★★★☆☆☆
|
|
AB Dynamics
|
NA
|
2.2x
|
35.13%
|
★★★☆☆☆
|
Click here to see the full list of 85 stocks from our Undervalued European Small Caps With Insider Buying screener.
We’ll examine a selection from our screener results.
Simply Wall St Value Rating: ★★★★☆☆
Overview: BioPharma Credit focuses on investing in debt assets secured by royalties within the biopharmaceutical sector and has a market capitalization of approximately $1.10 billion.
Operations: The company generates revenue primarily from investments in debt assets secured by royalties, with recent figures showing $157.75 million in this segment. Operating expenses are consistently around $27.90 million to $31.56 million, impacting the net income margin which has been observed at levels such as 82.34%. Gross profit margin is consistently at 100%, indicating that there are no costs of goods sold affecting the gross profit calculation.
PE: 8.2x
BioPharma Credit, a player in the life sciences sector, is considered undervalued among European small caps. Recent earnings for 2025 showed revenue at US$157.78 million and net income at US$129.89 million, both up from the previous year. Their commitment to shareholder returns is evident with a consistent dividend strategy, including an interim dividend of 1.75 cents per share announced for May 2026. They recently entered into a significant loan agreement with Zenas BioPharma worth up to US$125 million, highlighting their strategic investment approach despite reliance on external borrowing as their funding source.
LSE:BPCR Share price vs Value as at May 2026
Simply Wall St Value Rating: ★★★☆☆☆
Overview: Invisio specializes in advanced communication systems designed to enhance auditory protection and clarity for military and security forces, with a market capitalization of approximately SEK 13.56 billion.
Operations: Invisio generates revenue primarily from its sales, with a significant focus on maintaining a balance between cost management and profitability. The company’s gross profit margin has shown variability, reaching as high as 60.48% in recent periods, indicating an effective management of production costs relative to sales. Operating expenses are a substantial component of the cost structure, with notable allocations towards Sales & Marketing and R&D activities.
PE: 52.9x
Invisio, a small European company, reported a significant increase in Q1 2026 sales to SEK 430.5 million from SEK 334.8 million the previous year, reflecting its growth potential despite relying entirely on external borrowing for funding. Insider confidence is evident with recent share purchases, suggesting optimism about future prospects. While earnings per share have risen slightly, the company’s forecasted annual earnings growth of 33% hints at promising developments ahead in their industry niche.
OM:IVSO Share price vs Value as at May 2026
Simply Wall St Value Rating: ★★★★☆☆
Overview: Nivika Fastigheter is a Swedish real estate company focused on owning, managing, and developing residential and commercial properties, with a market capitalization of approximately SEK 5.25 billion.
Operations: Nivika Fastigheter generates revenue through its operations, which have shown a gross profit margin ranging from 65.99% to 82.58% over the periods analyzed. The company experiences fluctuations in net income, with recent periods showing negative net income margins due to significant non-operating expenses impacting profitability. Operating expenses are consistently recorded, with general and administrative expenses forming a notable portion of these costs.
PE: 11.3x
Nivika Fastigheter, a European property company, recently reported strong first-quarter results with net income doubling to SEK 124 million from the previous year. Despite earnings forecasted to decline by 4.1% annually over three years, revenue is expected to grow by 7.2% per year. Insider confidence is evident as director Tim Floderus purchased 50,000 shares for approximately SEK 2.18 million in April, signaling potential value recognition within the company’s stock amidst its financial challenges and sustainability initiatives like a new SEK 200 million loan linked to environmental targets.
OM:NIVI B Share price vs Value as at May 2026 Summing It All Up Searching for a Fresh Perspective?
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include LSE:BPCR OM:IVSO and OM:NIVI B.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
